Lakewood-Amedex Biotherapeutics Inc. finished a deal to buy back all its Series C shares for $1,270,970.

Nov 10, 2026, 5:22 PM ETNew sharesRead the original at SEC EDGAR

Neutral

LABT used $1,270,970 in cash and agreed to cover certain losses for the holder while canceling all convertible preferred shares. Removing the shares helps, but the cash use and added promise work against that benefit, leaving no clear change to LABT's outlook.

LABT · Lakewood-Amedex Biotherapeutics Inc.

AI read · Neutral

The AI's read

Removing the preferred shares ends the possibility of future conversions from those shares. The company also spent cash and agreed to cover certain losses for the holder. The filing gives no amount for those duties or for the company's remaining cash, so the facts point in different directions.

Get alerts for LABT

Follow Lakewood-Amedex Biotherapeutics Inc. (LABT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LABT

Free on the App Store and Google Play, or on the web.